• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD

BD unveils ultrasound tech for IV insertions

April 11, 2023 By Sean Whooley

BD Prevue II ultrasound guidance for IV placement

BD (NYSE:BDX) announced today that it launched a new ultrasound device to help clinicians achieve optimal IV placement. The new, easy-to-use, advanced ultrasound device — called the Prevue II — features a special probe. BD designed the Prevue II to address an unmet need in IV access through real-time needle depth markers. Franklin Lakes, New […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: BD

BD issues vulnerability warning for Alaris infusion monitoring software

February 16, 2023 By Sean Whooley

BD Alaris Infusion Central software

BD (NYSE:BDX) today issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. Alaris Infusion Central, a standalone software — separate from pumps — provides data from the Alaris pumps. It allows healthcare providers to monitor infusion data sent from Alaris Plus and Alaris neXus pumps on a computer. Alaris Infusion Central […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Recalls, Regulatory/Compliance Tagged With: Alaris, BD

How Embecta started strong and what’s ahead for the BD diabetes spinoff

February 2, 2023 By Sean Whooley

Embecta CEO Devdatt Dev Kurdikar headshot

Ten months after spinning off from BD, Embecta CEO Dev Kurdikar lays out what the future holds for the diabetes technology company. When Embecta became a standalone company in April 2022, CFO Jake Elguicze said he felt it was “uniquely positioned.” As a pure-play diabetes technology developer, its beginning phase hardly mirrors a normal startup. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Research & Development, Technology Tagged With: BD, embecta

The 10 biggest diabetes tech stories from 2022

December 27, 2022 By Sean Whooley

Diabetes stories 2022 insulet dexcom abbott senseonics

2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Recalls, Regulatory/Compliance, Technology, Wall Street Beat Tagged With: abbott, BD, CamDiab, Dexcom, embecta, Insulet, Medtronic, Senseonics, Sernova Inc, Tandem Diabetes Care, Ypsomed

Embecta stock slides on mixed Q4 results

December 20, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

Analysts remain neutral on Embecta, await insulin patch pump developments

December 16, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

BD opens $38.6M medication management manufacturing plant in Mexico

December 2, 2022 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) announced recently that it inaugurated a new $38.6 million manufacturing facility in Tijuana, Mexico. Government officials from Mexico and the state of Baja California joined in the opening of the medication management plant. BD plans for the facility to produce devices and technologies that improve medication safety within healthcare settings. According to a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD

BD warns on cybersecurity risk with BodyGuard infusion pumps

December 1, 2022 By Sean Whooley

BD BodyGuard infusion pump

The U.S. Cybersecurity and Infrastructure Security Agency (CISA) today issued an advisory regarding infusion pumps from BD (NYSE:BD). CISA’s advisory concerns the BD BodyGuard infusion pumps. They may contain a vulnerability in the form of a missing protection mechanism for an alternate hardware interface. No known public exploits specifically target this vulnerability, CISA said. Attackers […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: BD, Cybersecurity

BD, Biocorp partner on connectivity for self-administered injectable drugs

October 18, 2022 By Sean Whooley

BD Biocorp

BD (NYSE:BDX) announced that it entered into an agreement with Biocorp with the aim to use connected technology with injectable drugs. The companies seek to track adherence for self-administered drug therapies, including biologics. They plan to integrate France-based Biocorp’s Injay technology with BD’s UltraSafe Plus passive needle guard. Biocorp designed Injay to capture and transmit […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, biocorp

BD names new president of medication delivery

October 3, 2022 By Sean Whooley

Eric Borin BD President of Medication Delivery Solutions

BD (NYSE:BDX) announced today that it named Eric Borin as its president of medication delivery solutions (MDS). Borin, 55, succeeds Rick Byrd in the role. Byrd recently received a promotion to EVP and president of BD’s interventional segment. As president of medication delivery solutions, Borin will report to Mike Garrison, EVP and president of the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel, Pharmaceuticals Tagged With: BD, Personnel, Personnel Moves

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS